Physician profile
Daniel David Ring
NPI 1669987012
$7,807.83
in general payments reported to CMS, 2019-2025
41 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $752 · 2022: $2,139 · 2023: $2,219 · 2024: $2,173 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,850 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,850.18 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $997.29 | 2021-2025 | |
| Novo Nordisk INC | $969.54 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $815.72 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $788.22 | 2021-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals Lp | $782.15 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $731.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $563.04 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.18 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $264.55 | 2022-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $230.33 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $105.15 | 2021-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $98.94 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.90 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $82.62 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $79.17 | 2025 | Voquezna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $70.14 | 2021-2022 | |
| Esperion Therapeutics, INC. | $55.10 | 2024 | Nexletol |
| Mylan Specialty L.P. | $51.34 | 2022-2023 | Yupelri |
| Amarin Pharma, INC. | $50.32 | 2021 | |
| Janssen Biotech, INC. | $49.25 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $44.44 | 2021-2022 | |
| Abbott Laboratories | $44.33 | 2022-2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $43.63 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $42.48 | 2021 | |
| Dexcom, INC. | $40.38 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.63 | 2022 | |
| Lundbeck LLC | $28.60 | 2024 | Rexulti |
| Currax Pharmaceuticals LLC | $27.37 | 2023-2024 | Contrave, Onzetra Xsail |
| E.R. Squibb & Sons, L.L.C. | $25.93 | 2021-2022 | |
| Grifols USA, LLC | $23.39 | 2024 | Prolastin-C Liquid |
| Antares Pharma, INC. | $22.51 | 2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.34 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $18.73 | 2022 | |
| Aimmune Therapeutics, INC. | $18.61 | 2025 | Zenpep |
| Silk Road Medical, INC. | $18.23 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Sanofi Pasteur INC. | $14.97 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.79 | 2022 | |
| Sumitomo Pharma America, INC. | $14.71 | 2023 | Gemtesa |
| Nevro Corp. | $14.02 | 2023 | Senza |
| Janssen Pharmaceuticals, INC | $13.86 | 2022 | |
| Genentech USA, INC. | $2.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.